Ardea Biosciences, Inc. (NASDAQ: RDEA) is on The StockGuru Leader Board today. The stock is up as much as 51.63% on Monday.
Volume traded – so far – as this release was issued intraday: 25,500,185
Join in on the Discussion about RDEA: http://members.stockguru.com/stocks/rdea/
About the Company:
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Its product candidates include Lesinurad (RDEA594), an inhibitor of the URAT1 kidney transporter, which is in Phase III clinical trials for the treatment of gout; BAY 86-9766 (RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor that is in Phase II clinical trials for the treatment of cancer; and RDEA3170, an URAT1 kidney transporter inhibitor, which is in Phase I clinical trials for the treatment of gout. The company has a development and commercialization license agreement with Bayer Healthcare AG to develop and commercialize MEK inhibitors for various indications. Ardea Biosciences, Inc. is based in San Diego, California.
About the StockGuru Leader Board:
We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.
Feel free to suggest a stock for coverage if you see it breaking out. Contact: firstname.lastname@example.org.
All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: Publisher@StockGuru.com or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070